Asset profile
Brenipatide
Peptide
Evidence outlook · registrational
Major Depressive Disorder: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-02.
Also in development:Obesity · Phase 1Schizophrenia · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
189 competitors in this universe: 11 direct rivals (same mechanism and indication), 1 same-class, 177 same-indication; 51 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Brenipatide: this drug | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| HDM1005 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| HS-20094 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| KP405 | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor |
…and 174 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
2 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (6)
February 2027 (2)
July 2027 (1)
What to watch
September 2027 (1)
What to watch
2028 (7)
February 2028 (1)
What to watch
March 2028 (1)
What to watch
April 2028 (3)
What to watch
What to watch
May 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.